Development of adoptive immunotherapy technology in post-transplantation period

Освоение технологии адоптивной иммунотерапии в пост трансплантационный период.
Yuriy Kim 1, Samat Saparbayev 1, Bolatbek Kayupov 1, Zhuldyzay Kassymova 1, Aynara Darbayeva 1
More Detail
1 Center for cell technology and transplantation National Scientific Medical Research Center, Astana city, Kazakhstan
J CLIN MED KAZ, Volume 2, Issue 32, pp. 73-75.
OPEN ACCESS
Download Full Text (PDF)

ABSTRACT

After liver transplantation due to recurrent HCV infection, recurrence of hepatocellular carcinoma is common. It leads to graft loss and patient’s death. Adoptive immunotherapy based on natural killers has huge potential in prevention of hepatitis C recurrence and subsequent hepatocellular carcinoma development.

CITATION

Kim Y, Saparbayev S, Kayupov B, Kassymova Z, Darbayeva A. Development of adoptive immunotherapy technology in post-transplantation period. Journal of Clinical Medicine of Kazakhstan. 2014;2(32):73-5.

REFERENCES

  • Possibility of adoptive immunotherapy with peripheral blood-derived CD3CD56+ and CD3+CD56+ cells for inducing antihepatocellular carcinoma and antihepatitis C virus activity. Doskali M, Tanaka Y, Ohira M, Ishiyama K, Tashiro H, Chayama K, Ohdan H.
  • Adoptive immunotherapy with liver allograft–derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. Masahiro Ohira, Kohei Ishiyama, Yuka Tanaka, Marlen Doskali, Yuka Igarashi, Hirotaka Tashiro, Nobuhiko Hiraga, Michio Imamura, Naoya Sakamoto,Toshimasa Asahara, Kazuaki Chayama and Hideki Ohdan // J Clin Invest. 2009.-Vol.119(11).-P.3226–3235.